Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma

Conclusions: 1) OMA allowed a significant OC reduction. 2) OMA G. showed a clinical improvement which correlated with the improvement in bronchial pathology. 3) OMA allowed an improvement in bronchial remodeling. 4) The presence of e-cadherin in the biopsies may suggest that the lack of differences in the EGFR immunostaining was due to mucosal denudation. 5) Treatment with OMA was well-tolerated.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Domingo Ribas, C., Gonzalez-Barcala, F. J., Garcia, F., Morina, D., Salgado, F. J., Marco, V., Oliva, J. C., Mirapeix, R. M. Tags: Airway pharmacology and treatment Source Type: research